{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:20:23Z","timestamp":1778894423593,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Alopecia areata (AA) is an autoimmune-mediated inflammatory dermatological disease characterised by non-scarring hair loss affecting the scalp and sometimes other hair-bearing sites. This study aimed to elicit health state utility values (HSUVs) from the UK general population for AA using time trade off (TTO) interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Vignette descriptions of health states defined by the extent of hair loss were developed (as well as one describing caregiver burden). These were developed using data from standardised patient reported outcome (PRO) measures, a literature review and qualitative interviews. Health states were defined based on the severity of alopecia tool (SALT), which assesses extensiveness of scalp hair loss. HSUVs were then elicited for each health state in TTO interviews with the UK public.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One caregiver and five patient health states were developed based on the literature review findings, clinical trial PRO (Hospital Anxiety and Depression Scale and Alopecia Areata Patient Priority Outcomes Questionnaire) data and qualitative interviews with patients (<jats:italic>N<\/jats:italic>\u2009=\u200911), clinical experts (<jats:italic>N<\/jats:italic>\u2009=\u20094) and caregivers of adolescents with AA (<jats:italic>N<\/jats:italic>\u2009=\u200910). These data showed a more severe impact among patients with more extensive hair loss. One hundred and twenty participants evaluated the vignettes in TTO interviews. Patient HSUVs ranged from 0.502 for the most extensive hair loss health state (SALT 50\u2013100\u2009+\u2009eyebrow and eyelash loss) to 0.919 (SALT 0\u201310) for the mildest health state. The caregiver HSUV was 0.882.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Quantitative and qualitative data sources were used to develop and validate vignettes describing different AA health states. Patient and caregiver HSUVs demonstrate a large impact associated with AA, especially for states defined by more extensive hair loss.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11136-024-03645-9","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T05:01:48Z","timestamp":1711688508000},"page":"1581-1592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Estimation of health utility values for alopecia areata"],"prefix":"10.1007","volume":"33","author":[{"given":"Daniel","family":"Aggio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowena","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"3645_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. (2017). Alopecia areata. Nature Reviews Disease Primers, 3, 1.","journal-title":"Nature Reviews Disease Primers"},{"issue":"2","key":"3645_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell, W. C., Lai, V. W., Photiou, L., Meah, N., Wall, D., Rathnayake, D., Joseph, S., Chitreddy, V., Gunatheesan, S., Sindhu, K., & Sharma, P. (2019). Treatment of alopecia areata: An Australian expert consensus statement. Australasian Journal of Dermatology, 60(2), 163\u2013170.","journal-title":"Australasian Journal of Dermatology"},{"issue":"3","key":"3645_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., McMichael, A. J., Randall, V. A., & Turner, M. L. (2004). Alopecia areata investigational assessment guidelines\u2013Part II. Journal of the American Academy of Dermatology, 51(3), 440\u2013447.","journal-title":"Journal of the American Academy of Dermatology"},{"key":"3645_CR4","unstructured":"Alopecia areata\u2014Level 3 cause | Institute for Health Metrics and Evaluation. Retrieved November 1, 2021 from http:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/alopecia-areata-level-3-cause"},{"issue":"2","key":"3645_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries, M., Macbeth, A. E., Holmes, S., Chiu, W. S., Gallardo, W. R., Nijher, M., de Lusignan, S., Tziotzios, C., & Messenger, A. G. (2022). The epidemiology of alopecia areata: A population-based cohort study in UK primary care. British Journal of Dermatology, 186(2), 257.","journal-title":"British Journal of Dermatology"},{"key":"3645_CR6","first-page":"397","volume":"2015","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke, A. C., & Miteva, M. (2015). Epidemiology and burden of alopecia areata: A systematic review. Clinical Cosmetic and Investigational Dermatology, 2015, 397\u2013403.","journal-title":"Clinical Cosmetic and Investigational Dermatology"},{"key":"3645_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi, A., Napatalung, L., Sikirica, V., Winnette, R., Xenakis, J., Zwillich, S. H., & Gorsh, B. (2021). Patient perspectives of the social, emotional and functional impact of alopecia areata: A systematic literature review. Dermatology and Therapy, 11, 867\u2013883. https:\/\/doi.org\/10.1007\/s13555-021-00512-0","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"3645_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz, F., Gul\u00e1csi, L., P\u00e9ntek, M., Wikonk\u00e1l, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology., 175(3), 561\u2013571. https:\/\/doi.org\/10.1111\/bjd.14497","journal-title":"British Journal of Dermatology."},{"issue":"5","key":"3645_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jdv.13520","volume":"30","author":"S Jankovi\u0107","year":"2016","unstructured":"Jankovi\u0107, S., Peri\u0107, J., Maksimovi\u0107, N., \u0106irkovi\u0107, A., Marinkovi\u0107, J., Jankovi\u0107, J., Relji\u0107, V., & Medenica, L. (2016). Quality of life in patients with alopecia areata: A hospital-based cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 30(5), 840\u2013846. https:\/\/doi.org\/10.1111\/jdv.13520","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"3645_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13555-021-00508-w","volume":"11","author":"R Winnette","year":"2021","unstructured":"Winnette, R., Martin, S., Harris, N., & Deal, L. S. (2021). Development of the alopecia areata patient priority outcomes instrument: A qualitative study. Dermatology and Therapy, 11, 599\u2013613.","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"3645_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bodyim.2009.03.004","volume":"6","author":"N Welsh","year":"2009","unstructured":"Welsh, N., & Guy, A. (2009). The lived experience of alopecia areata: A qualitative study. Body Image, 6(3), 194\u2013200.","journal-title":"Body Image"},{"key":"3645_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/983804","author":"J Masmoudi","year":"2013","unstructured":"Masmoudi, J., Sellami, R., Ouali, U., Mnif, L., Feki, I., Amouri, M., et al. (2013). Quality of life in alopecia areata: A sample of Tunisian patients. Dermatology Research and Practice. https:\/\/doi.org\/10.1155\/2013\/983804","journal-title":"Dermatology Research and Practice."},{"issue":"4","key":"3645_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu, L. Y., King, B. A., & Craiglow, B. G. (2016). Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. Journal of the American Academy of Dermatology, 75(4), 806\u2013812.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"3645_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/ijt.ijt_93_18","volume":"10","author":"SJ Li","year":"2018","unstructured":"Li, S. J., Huang, K. P., Joyce, C., & Mostaghimi, A. (2018). The impact of alopecia areata on sexual quality of life. International Journal of Trichology, 10(6), 271\u2013274.","journal-title":"International Journal of Trichology"},{"issue":"1","key":"3645_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NV Aldhouse","year":"2020","unstructured":"Aldhouse, N. V., Kitchen, H., Knight, S., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., King, B. A., & Wyrwich, K. W. (2020). \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019I was so embarrassed, I was so self-conscious, I was so depressed:\u201d A qualitative interview study to understand the psychosocial burden of alopecia areata. Journal of Patient-Reported Outcomes, 4(1), 76. https:\/\/doi.org\/10.1186\/s41687-020-00240-7","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"2","key":"3645_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/jdv.15927","volume":"34","author":"G Titeca","year":"2020","unstructured":"Titeca, G., Goudetsidis, L., Francq, B., Sampogna, F., Gieler, U., Tomas-Aragones, L., Lien, L., Jemec, G. B., Misery, L., Szab\u00f3, C., & Linder, D. (2020). \u2018The psychosocial burden of alopecia areata and androgenetica\u2019: A cross-sectional multicentre study among dermatological out-patients in 13 European countries. Journal of the European Academy of Dermatology and Venereology, 34(2), 406\u2013411.","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5","key":"3645_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","volume":"166","author":"AG Messenger","year":"2012","unstructured":"Messenger, A. G., McKillop, J., Farrant, P., McDonagh, A. J., Sladden, M., Hughes, J., McLelland, J., Punjabi, S., Buckley, D. A., Nasr, I., & Swale, V. J. (2012). British Association of Dermatologists\u2019 guidelines for the management of alopecia areata 2012. British Journal of Dermatology, 166(5), 916\u2013926.","journal-title":"British Journal of Dermatology"},{"key":"3645_CR18","doi-asserted-by":"publisher","first-page":"950450","DOI":"10.3389\/fphar.2022.950450","volume":"13","author":"D Yan","year":"2022","unstructured":"Yan, D., Fan, H., Chen, M., & Nie, X. (2022). The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies. Frontiers in Pharmacology, 13, 950450.","journal-title":"Frontiers in Pharmacology"},{"key":"3645_CR19","unstructured":"A phase 3 study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata (THRIVE-AA2)\u2014full text view. ClinicalTrials.gov. Retrieved March 3, 2023 from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04797650"},{"key":"3645_CR20","unstructured":"A study of Baricitinib (LY3009104) in adults with severe or very severe alopecia areata-full text view-ClinicalTrials.gov. Retrieved March 3, 2023 from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03899259"},{"key":"3645_CR21","unstructured":"PF-06651600 for the treatment of alopecia areata-full text view-ClinicalTrials.gov. Retrieved March 3, 2023 from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807"},{"key":"3645_CR22","unstructured":"NICE health technology evaluations: The manual process and methods. Retrieved November 10, 2022 from www.nice.org.uk\/process\/pmg36"},{"key":"3645_CR23","unstructured":"Overview | Baricitinib for treating moderate to severe atopic dermatitis | Guidance | NICE. Retrieved March 26, 2023 from https:\/\/www.nice.org.uk\/guidance\/ta681"},{"issue":"12","key":"3645_CR24","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1016\/j.jval.2022.09.2133","volume":"25","author":"A Bewley","year":"2022","unstructured":"Bewley, A., Galv\u00e1n, S. V., Johansson, E., Austin, J., Durand, F., Petto, H., Piraccini, B. M., & Blume-Peytavi, U. (2022). PCR200 measuring the burden of alopecia areata with the European quality of life-5 dimensions (EQ-5D): Results from a real-world survey in 5 European countries. Value in Health, 25(12), S428\u2013S429.","journal-title":"Value in Health"},{"issue":"3","key":"3645_CR25","doi-asserted-by":"publisher","first-page":"AB86","DOI":"10.1016\/j.jaad.2021.06.368","volume":"85","author":"RT Burge","year":"2021","unstructured":"Burge, R. T., Anderson, P., Austin, J., Piercy, J., Manuel, L., Edson-Heredia, E., McCollam, J. S., & Senna, M. (2021). The patient-reported burden of alopecia areata by current severity: A real-world study in the US. Journal of the American Academy of Dermatology, 85(3), AB86.","journal-title":"Journal of the American Academy of Dermatology"},{"key":"3645_CR26","first-page":"1","volume":"7","author":"D Rowen","year":"2020","unstructured":"Rowen, D., Brazier, J., Wong, R., & Wailoo, A. (2020). Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available. NICE DSU Rep, 7, 1\u201348.","journal-title":"NICE DSU Rep"},{"issue":"6","key":"3645_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza, L. S., Stewart, K. D., Lloyd, A. J., Rowen, D., & Brazier, J. E. (2021). Vignette-based utilities: Usefulness, limitations, and methodological recommendations. Value in Health, 24(6), 812\u2013821.","journal-title":"Value in Health"},{"key":"3645_CR28","volume-title":"NICE DSU technical support document 11: Alternatives to EQ-5D for generating health state utility values","author":"J Brazier","year":"2017","unstructured":"Brazier, J., & Rowen, D. (2017). NICE DSU technical support document 11: Alternatives to EQ-5D for generating health state utility values. London: NICE."},{"issue":"10387","key":"3645_CR29","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King, B., Zhang, X., Harcha, W. G., Szepietowski, J. C., Shapiro, J., Lynde, C., Mesinkovska, N. A., Zwillich, S. H., Napatalung, L., Wajsbrot, D., & Fayyad, R. (2023). Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b\u20133 trial. The Lancet, 401(10387), 1518\u20131529.","journal-title":"The Lancet"},{"issue":"12","key":"3645_CR30","doi-asserted-by":"publisher","first-page":"S402","DOI":"10.1016\/j.jval.2022.09.1998","volume":"25","author":"B Hauber","year":"2022","unstructured":"Hauber, B., Whichello, C., Mauer, J., Law, E., Trapali, M., Whalen, E. P., Wajsbrot, D., Krucien, N., Tervonen, T., Zwillich, S., & Wolk, R. (2022). PCR63 using patient preference to inform ritlecitinib dose selection for alopecia areata treatment. Value in Health, 25(12), S402.","journal-title":"Value in Health"},{"key":"3645_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith, R. P. (2003). The hospital anxiety and depression scale. Health and Quality of Life Outcomes, 1, 1\u20134.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"1","key":"3645_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-021-00648-z","volume":"12","author":"KW Wyrwich","year":"2022","unstructured":"Wyrwich, K. W., Winnette, R., Bender, R., Gandhi, K., Williams, N., Harris, N., & Nelson, L. (2022). Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatology and Therapy, 12(1), 149\u2013166.","journal-title":"Dermatology and Therapy"},{"key":"3645_CR33","unstructured":"2011 Census\u2014Office for National Statistics. Retrieved August 22, 2022 from https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/2011censuspopulationestimatesfortheunitedkingdom\/2012-12-17"},{"key":"3645_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"M Oppe","year":"2016","unstructured":"Oppe, M., Rand-Hendriksen, K., Shah, K., Ramos-Go\u00f1i, J. M., & Luo, N. (2016). EuroQol protocols for time trade-off valuation of health outcomes. PharmacoEconomics, 34, 993\u20131004.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"3645_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/hec.1596","volume":"20","author":"NJ Devlin","year":"2011","unstructured":"Devlin, N. J., Tsuchiya, A., Buckingham, K., & Tilling, C. (2011). A uniform time trade off method for states better and worse than dead: feasibility study of the \u2018lead time\u2019approach. Health Economics, 20(3), 348\u2013361.","journal-title":"Health Economics"},{"key":"3645_CR36","unstructured":"1.13 Citing R | An introduction to R. Retrieved January 13, 2023 from https:\/\/intro2r.com\/citing-r.html"},{"key":"3645_CR37","unstructured":"Package \u201ceq5d\u201d type package title methods for analysing \u201cEQ-5D\u201d data and calculating \u201cEQ-5D\u201d index scores. Retrieved January 13, 2023 from https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/"},{"key":"3645_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13555-020-00477-6","volume":"11","author":"J Macey","year":"2021","unstructured":"Macey, J., Kitchen, H., Aldhouse, N. V., Burge, R. T., Edson-Heredia, E., McCollam, J. S., Isaka, Y., & Torisu-Itakura, H. (2021). Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in Japan. Dermatology and Therapy, 11, 433\u2013447.","journal-title":"Dermatology and Therapy"},{"issue":"4","key":"3645_CR39","first-page":"140","volume":"14","author":"M Ghajarzadeh","year":"2011","unstructured":"Ghajarzadeh, M., Ghiasi, M., & Kheirkhah, S. (2011). Depression and quality of life in Iranian patients with alopecia areata. Iranian Journal of Dermatology, 14(4), 140\u2013143.","journal-title":"Iranian Journal of Dermatology"},{"issue":"8","key":"3645_CR40","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jdv.17370","volume":"35","author":"PV Chernyshov","year":"2021","unstructured":"Chernyshov, P. V., Tomas-Aragones, L., Finlay, A. Y., Manolache, L., Marron, S. E., Sampogna, F., Spillekom-van Koulil, S., Pustisek, N., Suru, A., Evers, A. W. M., & Salavastru, C. (2021). Quality of life measurement in alopecia areata: Position statement of the European Academy of dermatology and venereology task force on quality of life and patient oriented outcomes. Journal of the European Academy of Dermatology and Venereology, 35(8), 1614\u20131621.","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"3645_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjd.19598","volume":"184","author":"I de Vere Hunt","year":"2021","unstructured":"de Vere Hunt, I., McNiven, A., & McPherson, T. (2021). A qualitative exploration of the experiences of adolescents with alopecia areata and their messages for healthcare professionals. British Journal of Dermatology, 184(3), 557\u2013559.","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"3645_CR42","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"JP Okhovat","year":"2023","unstructured":"Okhovat, J. P., Marks, D. H., Manatis-Lornell, A., Hagigeorges, D., Locascio, J. J., & Senna, M. M. (2023). Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 88(5), 1040\u20131050.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"3645_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu, L. Y., King, B. A., & Craiglow, B. G. (2018). Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. Journal of the American Academy of Dermatology, 79(3), 556\u2013558.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"3645_CR44","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jisp.2017.10.008","volume":"19","author":"AR Rodgers","year":"2018","unstructured":"Rodgers, A. R. (2018). Why finding a treatment for alopecia areata is important: A multifaceted perspective. Journal of Investigative Dermatology Symposium Proceedings., 19(1), S51\u2013S53.","journal-title":"Journal of Investigative Dermatology Symposium Proceedings."},{"key":"3645_CR45","unstructured":"(PDF) Impact on quality of life of family members of vitiligo patients in North India: A cross-sectional study using family dermatology life quality index. Retrieved February 1, 2023 from https:\/\/www.researchgate.net\/publication\/355264516_Impact_on_quality_of_life_of_family_members_of_vitiligo_patients_in_North_India_A_cross-sectional_study_using_family_dermatology_life_quality_index"},{"issue":"5","key":"3645_CR46","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jaad.2018.12.051","volume":"80","author":"E Putterman","year":"2019","unstructured":"Putterman, E., Patel, D. P., Andrade, G., Harfmann, K. L., Hogeling, M., Cheng, C. E., Goh, C., Rogers, R. S., & Castelo-Soccio, L. (2019). Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: A prospective, cross-sectional study. Journal of the American Academy of Dermatology, 80(5), 1389\u20131394.","journal-title":"Journal of the American Academy of Dermatology"},{"key":"3645_CR47","unstructured":"Census\u2014Office for National Statistics. Retrieved October 2023. https:\/\/www.ons.gov.uk\/census"},{"key":"3645_CR48","volume-title":"Self-reported population health: An international perspective based on EQ-5D","author":"B Janssen","year":"2014","unstructured":"Janssen, B., Szende, A., Janssen, B., & Szende, A. (2014). Self-reported population health: An international perspective based on EQ-5D. Springer."},{"issue":"5","key":"3645_CR49","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/bjd.18451","volume":"182","author":"L Andersen","year":"2020","unstructured":"Andersen, L., Nyeland, M. E., & Nyberg, F. (2020). Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the USA. British Journal of Dermatology, 182(5), 1176\u20131183.","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"3645_CR50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/13696998.2022.2059220","volume":"25","author":"KC Heinz","year":"2022","unstructured":"Heinz, K. C., Willems, D., & Hiligsmann, M. (2022). Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective. Journal of Medical Economics, 25(1), 491\u2013502. https:\/\/doi.org\/10.1080\/13696998.2022.2059220","journal-title":"Journal of Medical Economics"},{"issue":"12","key":"3645_CR51","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1111\/ced.15356","volume":"47","author":"I Mavranezouli","year":"2022","unstructured":"Mavranezouli, I., Welton, N. J., Daly, C. H., Wilcock, J., Bromham, N., Berg, L., Xu, J., Wood, D., Ravenscroft, J. C., Dworzynski, K., & Healy, E. (2022). Cost-effectiveness of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. Clinical and Experimental Dermatology, 47(12), 2176\u20132187.","journal-title":"Clinical and Experimental Dermatology"},{"key":"3645_CR52","unstructured":"Final appraisal determination-Omalizumab for previously treated chronic spontaneous urticaria. Retrieved 24 February, 2024 from https:\/\/www.nice.org.uk\/guidance\/ta339"},{"issue":"7","key":"3645_CR53","doi-asserted-by":"publisher","first-page":"A570","DOI":"10.1016\/j.jval.2016.09.1295","volume":"19","author":"K Hollis","year":"2016","unstructured":"Hollis, K., Abuzakouk, M., Balp, M., Berard, F., Canonica, G. W., Gimenez-Arnau, A., Grattan, C., Khalil, S., Knulst, A. C., Lacour, J., & Lynde, C. (2016). Assessing health-utility values for chronic spontaneous\/idiopathic urticaria in real-world using the EQ-5D: Results from assure-Csu study. Value in Health, 19(7), A570\u2013A571.","journal-title":"Value in Health"},{"key":"3645_CR54","doi-asserted-by":"publisher","first-page":"543290","DOI":"10.3389\/fmed.2020.543290","volume":"7","author":"Y Yuan","year":"2020","unstructured":"Yuan, Y., Xiao, Y., Chen, X., Li, J., & Shen, M. (2020). A systematic review and meta-analysis of health utility estimates in chronic spontaneous urticaria. Frontiers in Medicine, 7, 543290.","journal-title":"Frontiers in Medicine"},{"issue":"12","key":"3645_CR55","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","volume":"13","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2023","unstructured":"Va\u00f1\u00f3-Galv\u00e1n, S., Blume-Peytavi, U., Farrant, P., Reygagne, P., Johansson, E., Reed, C., Marwaha, S., Durand, F., & Piraccini, B. M. (2023). Physician-and patient-reported severity and quality of life impact of alopecia areata: Results from a real-world survey in five European countries. Dermatology and Therapy, 13(12), 3121\u20133135.","journal-title":"Dermatology and Therapy"},{"issue":"6","key":"3645_CR56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/bjd.17463","volume":"180","author":"L Davey","year":"2019","unstructured":"Davey, L., Clarke, V., & Jenkinson, E. (2019). Living with alopecia areata: An online qualitative survey study. British Journal of Dermatology, 180(6), 1377\u20131389.","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"3645_CR57","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska, N., King, B., Mirmirani, P., Ko, J., & Cassella, J. (2020). Burden of illness in alopecia areata: A cross-sectional online survey study. Journal of Investigative Dermatology Symposium Proceedings., 20(1), S62\u2013S68.","journal-title":"Journal of Investigative Dermatology Symposium Proceedings."},{"issue":"1","key":"3645_CR58","doi-asserted-by":"publisher","first-page":"26039","DOI":"10.3402\/qhw.v10.26039","volume":"10","author":"R Rafique","year":"2015","unstructured":"Rafique, R., & Hunt, N. (2015). Experiences and coping behaviours of adolescents in Pakistan with alopecia areata: An interpretative phenomenological analysis. International Journal of Qualitative Studies on Health and Well-being, 10(1), 26039.","journal-title":"International Journal of Qualitative Studies on Health and Well-being"},{"issue":"1","key":"3645_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi, A., Barton, V. R., Le, S. T., Agbai, O. N., & Kiuru, M. (2021). Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review. Journal of the American Academy of Dermatology, 85(1), 162\u2013175.","journal-title":"Journal of the American Academy of Dermatology"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03645-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03645-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03645-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:00:36Z","timestamp":1716472836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03645-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3645"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03645-9","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"1 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas Price, Rowena Randall and Ernest H. Law (Pfizer Inc.) are employees of and hold stock or stock options in Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was reviewed by the Western Institutional Review Board (WIRB) (May 2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave informed consent or assent prior to taking part in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}